Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1α on apolipoprotein D and GCDFP-15 expression in human breast cancer cells

Authors

  • Yves Blais,

    1. Medical Research Council Group in Molecular Endocrinology, CHUL Research Center and Laval University, Québec G1V 4G2, Canada
    Search for more papers by this author
  • Keiko Sugimoto,

    1. Medical Research Council Group in Molecular Endocrinology, CHUL Research Center and Laval University, Québec G1V 4G2, Canada
    Search for more papers by this author
  • Marie-Claude Carrière,

    1. Medical Research Council Group in Molecular Endocrinology, CHUL Research Center and Laval University, Québec G1V 4G2, Canada
    Search for more papers by this author
  • Darrow E. Haagensen,

    1. Department of Surgery, Methodist Hospital, Sacramento, CA 95823, USA
    Search for more papers by this author
  • Fernand Labrie,

    1. Medical Research Council Group in Molecular Endocrinology, CHUL Research Center and Laval University, Québec G1V 4G2, Canada
    Search for more papers by this author
  • Jacques Simard

    Corresponding author
    1. Medical Research Council Group in Molecular Endocrinology, CHUL Research Center and Laval University, Québec G1V 4G2, Canada
    • MRC Group in Molecular Endocrinology, CHUL Research Center, 2705 Laurier Boulevard, Québec, G1V 4G2, Canada
    Search for more papers by this author

Abstract

Our study was designed to investigate the potential interaction between steroid hormones and interleukin-6 (IL-6) in the regulation of apolipoprotein D (apo-D) and gross cystic disease fluid protein 15 (GCDFP-15) expression in ZR-75-1 human breast cancer cells. We first observed that exposure to IL-6 for 6–14 days decreased basal apo-D and GCDFP-15 secretion by 50% and 23%, respectively. In the same experiment, such treatment with IL-6 decreased cell proliferation by approximately 40% after 6 and 14 days of incubation. Exposure to IL-6 markedly decreased dihydrotestosterone (DHT)-induced apo-D and GCDFP-15 release, with a half-maximal effect measured at 13 U/ml. A similar inhibitory action of IL-6 was observed on the glucocorticoid dexamethasone (DEX)-induced apo-D and GCDFP-15 secretion. The sensitivity of the apo-D and GCDFP-15 response to the stimulatory action of DHT or DEX was, however, not changed by concomitant exposure to IL-6. The inhibitory effect of IL-6 on the secretion of these two biochemical markers was additive to that of 17β-estradiol. In addition, IL-6 blocked the stimulatory effect of interleukin-1α (IL-1α) on apo-D and GCDFP-15 secretion. Our results show that IL-6 is a potent inhibitor of basal as well as androgen-, glucocorticoid- and IL-1α-induced apo-D and GCDFP-15 secretion in ZR-75-1 human breast cancer cells, while cell proliferation is inhibited by this cytokine. © 1995 Wiley-Liss, Inc.

Ancillary